Alder Presents Positive Clinical Data for ALD403 at the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Alder Presents Positive Clinical Data for ALD403 at the 17th Congress of the International Headache Society

BOTHELL, Wash., May 15, 2015 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq: ALDR ), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide (CGRP) antibody for the prevention of frequent episodic migraine, were presented today by Jeffrey T.L. Smith, M.D., FRCP, Senior Vice President, Translational Medicine at Alder, in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain.

Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target:

  • A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine.
  • Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33% (p < 0.001); 33% vs 9% (p < 0.001); and 16% vs 0% (p < 0.001), respectively.
  • Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28% (p < 0.001); 26% vs 7% (p < 0.002); and 11% vs 0% (p <0.002), respectively.
  • ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data.
  • The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.

Alder also presented a poster with Phase 1 data for ALD403 titled, "A Single Dose Placebo-Controlled, Randomized, Ascending Dose Study of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody Administered IV or SC – Pharmacokinetic and Pharmacodynamic Results."

ALD403 is Alder's transformative novel monoclonal antibody that targets CGRP for prevention of migraine. CGRP is a small protein involved in the transmission of and heightened sensitivity to pain experienced in migraine.

Quote:

Randall C. Schatzman, Ph.D., President and Chief Executive Officer of Alder, said, "We believe that ALD403 has the potential to transform migraine prevention. These data presented today demonstrate the durable efficacy of ALD403 over six months, and we are now focused on identifying the optimal once-quarterly dose of ALD403 for both infusion and self-administration formulations. To this end, we plan to initiate two additional dose-ranging clinical trials in the second half of this year. We believe that providing patients and physicians the choice between these two routes of administration will allow a customized treatment paradigm that best suits each individual patient's preference and circumstances."

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead clinical candidate, ALD403, inhibits a well-validated molecule shown to trigger migraine attacks, calcitonin gene-related peptide (CGRP), and is currently undergoing Phase 2b clinical testing for the treatment of chronic migraines. Alder plans to initiate additional advanced clinical studies for ALD403 in frequent episodic and chronic migraines in the second half of 2015. Alder's second program, ALD1613, which targets adrenocorticotropic hormone (ACTH) is undergoing Investigational New Drug (IND)-enabling preclinical studies with the initiation of clinical studies in Cushing's disease planned for 2016. Finally, clazakizumab, previously known as ALD518, is designed to block the pro-inflammatory cytokine IL-6 and has completed a Phase 2b clinical trial. For more information, please visit http://www.alderbio.com .

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the further development of ALD403 and ALD1613, our expectations for the initiation of future clinical trials and studies, availability of clinical trial data, patient enrollment and the potential of ALD403, ALD1613 and clazakizumab to address the unmet medical needs of patients. All forward-looking statements included in this press release are based on our management's beliefs and assumptions and on information currently available to our management, and we assume no obligation to update any such forward-looking statements. Any or all of our forward-looking statements in this press release may turn out to be wrong and actual events or results may differ materially. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors. In evaluating these statements, you should specifically consider various factors, including the risks outlined under the caption "Risk Factors" set forth in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, which was filed with the Securities and Exchange Commission (SEC) on May 7, 2015, and is available on the SEC's website at www.sec.gov . Additional information will also be set forth in our other reports and filings we will make with the SEC from time to time. We caution investors that our business and financial performance are subject to substantial risks and uncertainties.

Media Contacts: David Schull or Lena Evans Russo Partners (212) 845-4271 (212) 845-4262 Investor Relations Contact: Sarah McCabe Stern Investor Relations, Inc. (212) 362-1200

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cytonics Refines CYT-108 Trial Plan With Decade OA Data

Updated Category News Views 89

A Better Map Is Not a Working Drug Knee osteoarthritis has chewed up plenty of promising development plans because the disease moves at an aggravatingly uneven crawl. Cytonics has done something sensible before pushing deeper into CYT-108: it went back to long-term untreated patient data and asked which knees actually deteriorate fast enough for a trial to detect...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 165

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 134

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 249

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Sinopec’s Algerian Outreach Reveals a Patient Long Game

Updated Category News Views 109

Soft Power Does Not Run a Refinery, but It Matters A short video contest in Algiers will not move an oilfield schedule or settle a hydrocarbons negotiation. That is precisely why this Sinopec-backed event deserves a sober look rather than a chest-thumping one. On Nov. 15, Sinopec Group and the Chinese Embassy in Algeria co-hosted the final of their second youth cultural...

Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!

Updated Category News Views 53

Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...

Continue Reading
BLLN Faces Fresh Questions After Short-Seller Report

Updated Category News Views 91

A six-percent air pocket is one thing; a disclosure mismatch is another beast entirely. BillionToOne shares fell on November 18 after short-seller Fuzzy Panda Research alleged the company had not disclosed meaningful regulatory scrutiny, including an alleged Tennessee matter in which regulators suspected fraud in 2024. That is an allegation from a short seller, not a...

Continue Reading
Veterans United Foundation Marks 15 Years of Giving

Updated Category News Views 62

A Milestone Measured in More Than Checks Fifteen years can turn a workplace charity into background noise, but this one plainly has not drifted into autopilot. Veterans United Foundation closed its 2026 anniversary campaign, called The Good Goes On, with $1.5 million directed to charitable organizations, 1,145 employee volunteers, and 2,680 hours of hands-on work. That is...

Continue Reading
APEC's Shared-Prosperity Message Needs More Detail

Updated Category News Views 50

Geese make handsome symbols, but markets cannot underwrite a metaphor. The Nov. 18, 2026 report from Xinhua News Agency looks back to remarks Chinese President Xi Jinping made 12 years ago, when he used swan geese to urge APEC economies toward greater cooperation and a new collective flight. Its present-day message is plainly hopeful: the APEC family is moving across the...

Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests

Updated Category News Views 89

Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...

Continue Reading

Top 5 Most Recently Viewed Articles

Wind River Launches Innovative eLxr Pro for Modern Deployments

Updated Category News Views 314

Transforming Edge Computing with eLxr Pro Wind River, a leader in intelligent edge software solutions, has just launched a groundbreaking product, eLxr Pro. This is a commercial enterprise Linux distribution tailored to meet the rising demands of cloud-to-edge deployments, significantly improving performance and operational capabilities across a range of sectors. Meeting...

Continue Reading
VirnetX Welcomes Dr. Jamison as New Chief Technical Officer

Updated Category News Views 541

VirnetX Appoints a New Chief Technical Officer VirnetX Holding Corporation (NYSE: VHC) is excited to announce the appointment of Dr. John Anthony Jamison as their new Chief Technical Officer (CTO). His extensive background significantly bolsters the team’s expertise in secure communications technology. Dr. Jamison's Impressive Background Dr. Jamison brings a wealth of...

Continue Reading
NDEX Systems Enhances Advisor Workflows with New Technology

Updated Category News Views 188

Innovative Integration by NDEX Systems MONTREAL — NDEX Systems, a leader in multi-custodian data utility and wealth-management solutions, has recently unveiled a new integration that significantly enhances the advisor experience. This development introduces a sophisticated single sign-on (SSO) connection and a fully integrated client onboarding process with the Schwab...

Continue Reading
Transforming Agriculture: The Rise of Regenerative Practices

Updated Category News Views 239

The Rise of Regenerative Agriculture In the current agricultural landscape, regenerative agriculture has emerged as a crucial response to the pressing issues of climate change, soil degradation, and food security. This innovative farming method doesn't just optimize food production; it revitalizes ecosystems and offers economic advantages for farmers around the globe....

Continue Reading
Ericsson's Q2 2025 Performance Highlights and Future Strategies

Updated Category News Views 367

Financial Overview of Q2 2025 Ericsson has reported significant advancements in its financial performance for the second quarter of 2025. With operational excellence, the company has seen a remarkable 48% adjusted gross margin, marking a three-year high in adjusted EBITA margin. This reflects a strong commitment to strategic execution and operational improvements....

Continue Reading